Investing.com -- Enliven Therapeutics (NASDAQ:ELVN) stock fell 7% on Tuesday following updates from multiple companies at the American Society of Hematology (ASH) Annual Meeting that could impact the competitive landscape in chronic myeloid leukemia (CML) treatments.
The decline came as Terns Pharmaceuticals (NASDAQ:TERN) presented promising data for its TERN-701 therapy in second-line CML treatment, positioning it as a potential competitor to Novartis’ (NYSE:NVS) Scemblix. Both drugs share the same mechanism of action, targeting the myristoyl-binding pocket.
Jones Trading analyst Soumit Roy noted that despite competitive pressures, Enliven’s ELVN-001, which targets the ATP-binding pocket, "remains well positioned in the 2L/2L+ setting" to treat patients who are refractory to treatments from Terns or Novartis.
At ASH, Enliven presented data showing ELVN-001’s activity against atypical BCR-ABL1 transcripts in its Phase 1 ENABLE trial. The company reported that two heavily pre-treated patients with rare atypical transcripts showed "deep and sustained benefit" from ELVN-001 treatment.
These atypical transcripts, which occur in approximately 2% of CML patients, can significantly alter treatment efficacy. Successfully targeting this difficult-to-treat population could expand ELVN-001’s potential market by an estimated 2,000-4,000 patients.
Meanwhile, Terns reported that its TERN-701 achieved a 74% overall major molecular response (MMR) rate in its Phase 1a dose escalation trial and 80% in its Phase 1b expansion trial, with a safety profile comparable to peers.
The competitive dynamics in the CML space continue to evolve, with analysts suggesting ELVN-001’s complementary mechanism of action could position it well as a follow-on treatment in second-line or later settings, particularly as myristoyl binding pocket inhibitors like Scemblix gain traction in first-line treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.








